AU2021417970A1 - Method for testing possibility of having contracted prostate cancer - Google Patents

Method for testing possibility of having contracted prostate cancer Download PDF

Info

Publication number
AU2021417970A1
AU2021417970A1 AU2021417970A AU2021417970A AU2021417970A1 AU 2021417970 A1 AU2021417970 A1 AU 2021417970A1 AU 2021417970 A AU2021417970 A AU 2021417970A AU 2021417970 A AU2021417970 A AU 2021417970A AU 2021417970 A1 AU2021417970 A1 AU 2021417970A1
Authority
AU
Australia
Prior art keywords
ions
prostate cancer
group
member selected
propan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021417970A
Other languages
English (en)
Other versions
AU2021417970A9 (en
Inventor
Kentaro Kobayashi
Kohei Matsunaga
Yoichi Mizutani
Atsufumi OZOE
Takaaki Sato
Yasuhiko Takahashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aino University
National Institute of Advanced Industrial Science and Technology AIST
Sumitomo Chemical Co Ltd
Original Assignee
Aino Univ
National Institute of Advanced Industrial Science and Technology AIST
Sumitomo Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aino Univ, National Institute of Advanced Industrial Science and Technology AIST, Sumitomo Chemical Co Ltd filed Critical Aino Univ
Publication of AU2021417970A1 publication Critical patent/AU2021417970A1/en
Publication of AU2021417970A9 publication Critical patent/AU2021417970A9/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/493—Physical analysis of biological material of liquid biological material urine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7206—Mass spectrometers interfaced to gas chromatograph
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/86—Signal analysis
    • G01N30/8624—Detection of slopes or peaks; baseline correction
    • G01N30/8631—Peaks
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2496/00—Reference solutions for assays of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
AU2021417970A 2021-01-07 2021-12-24 Method for testing possibility of having contracted prostate cancer Pending AU2021417970A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021001676 2021-01-07
JP2021-001676 2021-01-07
PCT/JP2021/048082 WO2022149487A1 (ja) 2021-01-07 2021-12-24 前立腺がんの罹患の可能性を検査する方法

Publications (2)

Publication Number Publication Date
AU2021417970A1 true AU2021417970A1 (en) 2023-07-27
AU2021417970A9 AU2021417970A9 (en) 2024-05-16

Family

ID=82357872

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021417970A Pending AU2021417970A1 (en) 2021-01-07 2021-12-24 Method for testing possibility of having contracted prostate cancer

Country Status (7)

Country Link
US (1) US20240085400A1 (https=)
EP (1) EP4276456A4 (https=)
JP (1) JP7769179B2 (https=)
CN (1) CN116783484A (https=)
AU (1) AU2021417970A1 (https=)
TW (1) TW202242412A (https=)
WO (1) WO2022149487A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013515270A (ja) * 2009-12-22 2013-05-02 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 前立腺癌の代謝学的プロファイリング
US20130217647A1 (en) * 2010-07-28 2013-08-22 Metabolon, Inc. Biomarkers for Prostate Cancer and Methods Using the Same
US20160025734A1 (en) * 2014-07-23 2016-01-28 Children's Medical Center Corporation Use of urinary protein biomarkers to distinguish between neoplastic and non-neoplastic disease of the prostate
JP2017203649A (ja) * 2016-05-09 2017-11-16 国立大学法人大阪大学 前立腺がん判定方法
CN108344830B (zh) * 2017-01-22 2020-10-16 中国科学院大连化学物理研究所 用于诊断前列腺癌的尿样组合标志物及检测试剂盒
US10908162B2 (en) * 2017-10-27 2021-02-02 The Board Of Regents Of The University Of Texas System Methods related to volatile compounds in genitourinary cancers

Also Published As

Publication number Publication date
EP4276456A4 (en) 2025-02-26
CN116783484A (zh) 2023-09-19
TW202242412A (zh) 2022-11-01
JP7769179B2 (ja) 2025-11-13
AU2021417970A9 (en) 2024-05-16
WO2022149487A1 (ja) 2022-07-14
JPWO2022149487A1 (https=) 2022-07-14
EP4276456A1 (en) 2023-11-15
US20240085400A1 (en) 2024-03-14

Similar Documents

Publication Publication Date Title
Shigeyama et al. Identification of volatile metabolites in human saliva from patients with oral squamous cell carcinoma via zeolite-based thin-film microextraction coupled with GC–MS
Silva et al. Solid phase microextraction, mass spectrometry and metabolomic approaches for detection of potential urinary cancer biomarkers—a powerful strategy for breast cancer diagnosis
US20050101023A1 (en) Methods for diagnosing urinary tract and prostatic disorders
EP2580596A1 (en) Methods to diagnose liver diseases
US20100273666A1 (en) Methods of analyzing wound samples
JP2019168319A (ja) 小児がん検査用尿中代謝物マーカー
JP7769179B2 (ja) 前立腺がんの罹患の可能性を検査する方法
Sawai et al. Serum levels of complement C4 fragments correlate with disease activity in multiple sclerosis: proteomic analysis
Negrei et al. Investigation relevance of methotrexate polyglutamates in biological systems by high performance liquid chromatography
JP2008533979A (ja) 生体細胞中の時間依存的な発現を防止するための試薬及び方法
El-Najjar et al. A rapid liquid chromatography-tandem mass spectrometry for the quantification of fosfomycin in plasma, urine, and aqueous fluids
Hayward et al. Post‐collection, pre‐measurement variables affecting VEGF levels in urine biospecimens
KR101202585B1 (ko) 암 특이적 당체 및 그 유도체를 이용한 암 진단을 위한 질량 스펙트럼 분석 방법
Ryu et al. Determination of cholesterol in human hair using gas chromatography–mass spectrometry
CN101122600A (zh) 一种血清小分子代谢产物的检测方法
Heier et al. Quantltation of serum complement components and plasma C3d in patients with malignant lymphoma: Relation to the stage of the tumor and circulating immune complexes
CA2525743A1 (en) Differential diagnosis of colorectal cancer and other diseases of the colon
JP7838771B2 (ja) 胆道がん検査方法
Komarevtseva et al. Alfa-1-Antitrypsin Predicts Severe COVID-19, Gastric and Renal Cancer in Conditions of Hyperglycemia
CN117147737B (zh) 用于食管鳞癌诊断的血浆组合标志物及试剂盒与检测方法
WO2021107792A1 (en) Method for assessing effectiveness of chemotherapeutic treatment of lung cancer, panel of metabolic biomarkers and kit for monitoring effectiveness of chemotherapeutic treatment of lung cancer
KR102775759B1 (ko) 반려견의 림프종 진단용 바이오마커
KR102957337B1 (ko) 반려견의 림프종 진단용 바이오마커
CN112881578A (zh) 一种用于肝癌预后风险评估的试剂盒及应用
WO2019067636A1 (en) ANALYSIS OF PROTEIN EXPRESSION FOR THE PROGNOSIS AND TREATMENT OF BREAST CANCER

Legal Events

Date Code Title Description
SREP Specification republished